BPA Call 36E79726A0010-36C24526N0785
Award Date 8/2/26
Potential Completion Date 9/30/26
Potential Value $51K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
Not listed Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Memphis, TN 38141, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, Veterans Integrated Service Network 5, issued a BPA call to Bristol-Myers Squibb Company on July 31, 2026, for POMALYST 3 MG with a ceiling value of $10,887.57 under the Pharmaceuticals and Drugs (FSS-61-IB) GSA Federal Supply Schedule. Place of performance is Memphis, Tennessee. The call carries an ultimate completion date of August 4, 2026. Pricing is firm fixed price. This order represents a narrow pharmaceutical supply call within Bristol-Myers Squibb's...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5, issued a BPA call to Bristol-Myers Squibb Company on May 27, 2026, for POMALYST 3 mg with a ceiling value of $10,887.57. The call was issued under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract, a comprehensive IDIQ vehicle covering drugs and pharmaceuticals across oncology, immunology, infectious diseases, and cardiology, with a master ceiling of $12.278 billion through April 30, 2029....
- The Department of Veterans Affairs, Veterans Integrated Service Network 5, issued a BPA call to Bristol-Myers Squibb Company on June 18, 2026, for Pomalidomide (Pomalyst) 4 mg capsules with a ceiling value of $16,421.95. The call was issued under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract, a comprehensive master agreement covering drugs and pharmaceuticals across multiple therapeutic areas including oncology and immunology, with a contract ceiling of $12.278...
- <p>Veterans Integrated Service Network 5 issued a BPA call to Bristol-Myers Squibb Company on May 21, 2026, for POMALYST 4 MG with a ceiling value of $16,421.95. The call is issued under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract with the Department of Veterans Affairs. Performance is located in Memphis, Tennessee. The order is firm fixed price with an ultimate completion date of May 26, 2026.</p>
- <p>The Department of Veterans Affairs, Veterans Integrated Service Network 5, issued a BPA call to Bristol-Myers Squibb Company on May 29, 2026, for POMALYST 2 MG, 3 MG, and 4 MG with a ceiling value of $149,435.80. The call was issued under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract. Performance occurs in Memphis, Tennessee, with an ultimate completion date of June 4, 2026. Pricing is firm fixed price with no set-aside designation.</p>
- The Veterans Integrated Service Network 5 issued a BPA call to Bristol-Myers Squibb Company on August 2, 2026, for POMALYST (pomalidomide) in 2 mg, 3 mg, and 4 mg strengths, with a ceiling value of $199,047.42 under the Pharmaceuticals and Drugs GSA Federal Supply Schedule (FSS-61-IB). The order is firm fixed price with an ultimate completion date of August 31, 2026. Place of performance is Memphis, Tennessee. POMALYST is an immunomodulatory agent supplied to the VA healthcare system for...
- Veterans Integrated Service Network 5 issued a BPA call to Bristol-Myers Squibb Company under the Pharmaceuticals and Drugs (FSS-61-IB) GSA Federal Supply Schedule with a ceiling value of $365,116.60, awarded January 29, 2026. The call covers supply of MAVACAMTEN (CAMZYOS) and POMALIDOMIDE (POMALYST) pharmaceutical products. Performance is located in Memphis, Tennessee, with ultimate completion by September 30, 2026. Pricing is firm fixed price. The GSA Federal Supply Schedule is a...
- The Veterans Integrated Service Network 5 issued a BPA call to Bristol-Myers Squibb Company on August 2, 2026, for Mavacamten (Camzyos) and Pomalidomide (Pomalyst) with a ceiling value of $300,000.00 under the GSA Federal Supply Schedule (Pharmaceuticals and Drugs, FSS-61-IB). Performance occurs in Memphis, Tennessee, with ultimate completion by September 30, 2026. The call is priced firm fixed price and draws from the multiple-award GSA FSS vehicle, which carries a $12.278 billion ceiling...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5, issued a BPA call to Bristol-Myers Squibb Company for CAMZYOS 5 MG with a ceiling value of $6,163.72, awarded April 7, 2026 and completing April 10, 2026. The call is issued under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract, a multiple-award indefinite delivery/indefinite quantity vehicle with a $12.28 billion ceiling extending through April 30, 2029. Performance occurs in Memphis,...
- Bristol-Myers Squibb Company has been awarded a delivery order valued at $127,169.40 for the supply of POMALYST (pomalidomide) in 2 mg and 4 mg formulations to support the Department of Veterans Affairs' Veterans Integrated Service Network 5 (VISN 5). This firm fixed-price contract is issued as a call against Bristol-Myers Squibb's existing Federal Supply Schedule contract (FSS-61-IB: Pharmaceuticals and Drugs) with the VA, which carries a ceiling value of $12.3 billion and extends through April...